GSIE - ETF AI Analysis
Top Page
Goldman Sachs ActiveBeta International Equity ETF (GSIE)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past few months, indicating positive recent momentum.
Leading Top Holdings
Several of the largest positions, including major technology and financial names, have delivered strong year-to-date results that support the fund’s overall performance.
Broad International Diversification
The fund spreads its investments across many countries and sectors, which helps reduce the impact if any single market or industry struggles.
Negative Factors
Moderate Expense Ratio
While not extremely high, the fund’s fee is higher than the cheapest index ETFs, which slightly reduces net returns over time.
Meaningful Financial Sector Exposure
A sizable allocation to financial companies means the fund can be more affected if banks and other financial firms face pressure.
Some Lagging Top Holding
At least one major position has shown weak performance this year, which can drag on the ETF’s overall results if it does not improve.
GSIE vs. SPDR S&P 500 ETF (SPY)
AUM5.64B
RegionDeveloped Markets
Expense Ratio0.25%
Beta0.71
IssuerGoldman Sachs
Inception DateNov 06, 2015
Dividend Yield2.54%
Asset ClassEquity
Index TrackedStuttgart Goldman Sachs ActiveBeta Intl.Equity (USD)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume385,362
30 Day Avg. Volume530,090
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.23Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering649
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSIE Summary
GSIE is the Goldman Sachs ActiveBeta International Equity ETF, which follows the Stuttgart Goldman Sachs ActiveBeta International Equity index and invests in stocks from many countries outside the U.S., such as Japan, the UK, and Europe. It owns a wide mix of companies across sectors, including well-known names like ASML, Novartis, HSBC, and Shell. Investors might consider GSIE to diversify beyond the U.S. market and seek long-term growth from international companies in one single fund. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?The expense ratio for the Goldman Sachs ActiveBeta International Equity ETF (GSIE) is 0.25%, which means you’ll pay $2.50 per year for every $1,000 invested. This is lower than average for actively managed ETFs because it uses a factor-based strategy rather than traditional stock-picking, keeping costs relatively modest.
What would affect this ETF?The GSIE ETF, with its focus on developed markets outside the U.S., could benefit from economic growth in Europe and Asia, particularly if industries like financials and technology, which have significant weight in the fund, experience expansion. However, it may face challenges from rising interest rates or geopolitical tensions that could negatively impact international markets and sectors like financials and consumer cyclical. Additionally, regulatory changes in key regions or currency fluctuations could influence the ETF's performance.
GSIE Top 10 Holdings
GSIE’s story is being written largely by big international banks and a handful of global champions. Financial heavyweights like HSBC, Royal Bank of Canada, Toronto-Dominion, and Banco Santander are rising together, giving the fund a solid tailwind from the banking sector. On the growth side, chip-equipment leader ASML and Japan’s Advantest are powering ahead, adding a tech spark despite their richer valuations. Health-care names are more mixed: AstraZeneca is steady, while Roche has been lagging and quietly tugging on returns. With holdings spread across Europe, Canada, and Japan, the ETF is firmly ex-U.S. but not tied to any single country or stock.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 1.83% | $101.84M | €477.33B | 106.32% | 76 Outperform | |
| Novartis AG | 1.05% | $58.50M | CHF207.57B | 22.14% | 80 Outperform | |
| HSBC Holdings | 1.05% | $58.10M | £226.99B | 58.35% | 80 Outperform | |
| Roche Holding AG | 1.04% | $57.75M | $327.04B | 22.13% | 73 Outperform | |
| Royal Bank Of Canada | 0.99% | $55.12M | $245.63B | 48.99% | 75 Outperform | |
| Advantest | 0.93% | $51.94M | ¥20.54T | 381.96% | 75 Outperform | |
| AstraZeneca | 0.89% | $49.53M | $292.69B | 32.74% | 80 Outperform | |
| Banco Santander | 0.80% | $44.62M | €149.64B | 62.09% | 73 Outperform | |
| Toronto Dominion Bank | 0.71% | $39.28M | $177.88B | 68.38% | 74 Outperform | |
| Shell (UK) | 0.66% | $36.95M | £184.86B | 32.32% | 73 Outperform |
GSIE Technical Analysis
Positive
―
Price Trends
44.39
Positive
44.13
Positive
42.30
Positive
Market Momentum
0.23
Positive
54.45
Neutral
42.32
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 45.13, equal to the 50-day MA of 44.39, and equal to the 200-day MA of 42.30, indicating a bullish trend. The MACD of 0.23 indicates Positive momentum. The RSI at 54.45 is Neutral, neither overbought nor oversold. The STOCH value of 42.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSIE.
GSIE Peer Comparison
Comparison Results
Performance Comparison
GSIE
Goldman Sachs ActiveBeta International Equity ETF
45.17
8.34
22.64%
LVHI
Legg Mason International Low Volatility High Dividend ETF
―
―
―
IMTM
iShares MSCI Intl Momentum Factor ETF
―
―
―
IDMO
Invesco S&P International Developed Momentum ETF
―
―
―
INTF
iShares MSCI Intl Multifactor ETF
―
―
―
PXF
Invesco FTSE RAFI Developed Markets ex-U.S. ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents